{"id":"imiquimod-vehicle","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erosion"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vehicle component serves as the pharmaceutical carrier for imiquimod, enabling topical delivery to skin lesions. Imiquimod itself works by binding to TLR7 and TLR8 on immune cells, triggering interferon and cytokine production that enhances local immune responses against viral infections and abnormal cells. The vehicle formulation optimizes drug penetration and retention at the site of application.","oneSentence":"Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:35.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"},{"name":"Basal cell carcinoma"},{"name":"Genital warts"}]},"trialDetails":[{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT04219358","phase":"PHASE1","title":"Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-03-23","conditions":"Actinic Cheilitis","enrollment":49},{"nctId":"NCT00189267","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2002-11","conditions":"Actinic Keratosis","enrollment":45},{"nctId":"NCT00189293","phase":"PHASE4","title":"Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2005-06","conditions":"Genital Warts","enrollment":128},{"nctId":"NCT00294320","phase":"PHASE3","title":"Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2006-02","conditions":"Actinic Keratosis","enrollment":12},{"nctId":"NCT02404389","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03-05","conditions":"Actinic Keratosis","enrollment":82},{"nctId":"NCT02482428","phase":"PHASE2","title":"Efficacy and Tolerability of Topical LFX453 for External Genital Warts","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-12","conditions":"External Genital Warts","enrollment":88},{"nctId":"NCT01686152","phase":"PHASE3","title":"Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2012-09","conditions":"Actinic Keratosis","enrollment":589},{"nctId":"NCT00948428","phase":"PHASE3","title":"Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2008-05","conditions":"Actinic Keratoses","enrollment":462},{"nctId":"NCT02120898","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2013-10-10","conditions":"Actinic Keratosis","enrollment":467},{"nctId":"NCT03071679","phase":"PHASE1","title":"Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers","status":"COMPLETED","sponsor":"Maruho Co., Ltd.","startDate":"2017-02-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT00470392","phase":"NA","title":"Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2007-05","conditions":"Psoriasis","enrollment":9},{"nctId":"NCT00828568","phase":"PHASE1","title":"Bioequivalence Study of Two Imiquimod Cream 5%","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":425},{"nctId":"NCT01788007","phase":"PHASE1","title":"Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-01","conditions":"Actinic Keratosis","enrollment":443},{"nctId":"NCT00079300","phase":"PHASE1","title":"Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"National Naval Medical Center","startDate":"2004-01","conditions":"Non-melanomatous Skin Cancer","enrollment":""},{"nctId":"NCT01567683","phase":"PHASE1","title":"A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01502020","phase":"NA","title":"A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2011-02","conditions":"Actinic Keratoses","enrollment":410},{"nctId":"NCT00335179","phase":"PHASE2","title":"Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2003-01","conditions":"Actinic Keratosis","enrollment":17},{"nctId":"NCT00859105","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"Apotex Inc.","startDate":"2008-02","conditions":"Actinic Keratosis","enrollment":497},{"nctId":"NCT00110682","phase":"PHASE4","title":"Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses","status":"COMPLETED","sponsor":"Derm Research @ 888 Inc.","startDate":"2005-04","conditions":"Keratosis, Actinic Keratosis","enrollment":60},{"nctId":"NCT00115154","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands","status":"COMPLETED","sponsor":"Graceway Pharmaceuticals, LLC","startDate":"2005-05","conditions":"Keratosis","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":153,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Imiquimod Vehicle","genericName":"Imiquimod Vehicle","companyName":"Apotex Inc.","companyId":"apotex-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod vehicle is a topical formulation base designed to deliver imiquimod, a toll-like receptor 7/8 agonist that activates innate immune responses. Used for Actinic keratosis, Basal cell carcinoma, Genital warts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}